Compare VHUB & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VHUB | NSRX |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 37.1M |
| IPO Year | 2025 | 2024 |
| Metric | VHUB | NSRX |
|---|---|---|
| Price | $0.19 | $2.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 129.1K | 11.6K |
| Earning Date | 11-16-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $864,450.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $1.98 |
| 52 Week High | $15.34 | $9.50 |
| Indicator | VHUB | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.74 | 31.72 |
| Support Level | N/A | $2.41 |
| Resistance Level | $0.29 | $3.61 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 2.29 | 4.52 |
Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.